Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease.

Inhaled corticosteroids are widely prescribed for the treatment of stable chronic obstructive pulmonary disease (COPD), despite lack of proven efficacy. Because COPD involves airway inflammation and probable protease-antiprotease imbalance, we examined the effect of high dose fluticasone propionate on markers of activity of both pathogenetic mechanisms. Thirteen patients with COPD were treated with fluticasone propionate (500 microg twice a day) for 4 wk, delivered via MDI and spacer, in a double-blind crossover study. There was no clinical benefit in terms of lung function or symptom scores, and induced sputum inflammatory cells, percentage neutrophils, and IL-8 levels were unchanged. Sputum supernatant elastase activity, matrix metalloproteinase (MMP)-1, MMP-9, and the antiproteases secretory leukoprotease inhibitor (SLPI) and tissue inhibitor of metalloproteinase (TIMP)-1 were similarly unaffected by treatment. These results add to previous evidence that inhaled steroids have no anti-inflammatory action in stable COPD. Furthermore, inhaled steroids do not appear to redress the protease-antiprotease imbalance that is thought to be important in the pathogenesis of airway obstruction.

[1]  B. Beghé,et al.  Inhaled corticosteroids reduce neutrophilic bronchial inflammation in patients with chronic obstructive pulmonary disease , 1998, Thorax.

[2]  P. Paggiaro,et al.  Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease , 1998, The Lancet.

[3]  S. Shapiro,et al.  Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice. , 1997, Science.

[4]  A Bast,et al.  Oxidative stress in chronic obstructive pulmonary disease. Oxidative Stress Study Group. , 1997, American journal of respiratory and critical care medicine.

[5]  L. O’Driscoll,et al.  Matrix metalloproteinase expression and production by alveolar macrophages in emphysema. , 1997, American journal of respiratory and critical care medicine.

[6]  C. O'connor,et al.  Elevated levels of matrix metalloproteinases in bronchoalveolar lavage fluid of emphysematous patients. , 1997, Thorax.

[7]  P. Barnes,et al.  Granulocyte activation markers in induced sputum: comparison between chronic obstructive pulmonary disease, asthma, and normal subjects. , 1997, American journal of respiratory and critical care medicine.

[8]  P. Barnes,et al.  Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. , 1997, American journal of respiratory and critical care medicine.

[9]  T. Tetley,et al.  Secretory leukoprotease inhibitor: partnering alpha 1-proteinase inhibitor to combat pulmonary inflammation. , 1996, Thorax.

[10]  R. Duranti,et al.  Role of sputum differential cell count in detecting airway inflammation in patients with chronic bronchial asthma or COPD. , 1996, Thorax.

[11]  F. Hargreave,et al.  Indices of airway inflammation in induced sputum: reproducibility and validity of cell and fluid-phase measurements. , 1996, American journal of respiratory and critical care medicine.

[12]  L. Fabbri,et al.  Airways obstruction, chronic expectoration, and rapid decline of FEV1 in smokers are associated with increased levels of sputum neutrophils. , 1996, Thorax.

[13]  P. Barnes,et al.  Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. , 1996, American journal of respiratory and critical care medicine.

[14]  R. Stockley,et al.  Effect of fluticasone propionate on sputum of patients with chronic bronchitis and emphysema. , 1996, American journal of respiratory and critical care medicine.

[15]  R. Stockley.  The role of proteinases in the pathogenesis of chronic bronchitis. , 1994, American journal of respiratory and critical care medicine.

[16]  S. Shapiro,et al.  Elastolytic metalloproteinases produced by human mononuclear phagocytes. Potential roles in destructive lung disease. , 1994, American journal of respiratory and critical care medicine.

[17]  G. Murphy,et al.  Structure-function relationships in the tissue inhibitors of metalloproteinases. , 1994, American journal of respiratory and critical care medicine.

[18]  C. O'connor,et al.  Matrix metalloproteases and lung disease. , 1994, Thorax.

[19]  R. Stockley,et al.  Effect of fluticasone propionate on neutrophil chemotaxis, superoxide generation, and extracellular proteolytic activity in vitro. , 1994, Thorax.

[20]  T. Ley,et al.  Cloning and characterization of a unique elastolytic metalloproteinase produced by human alveolar macrophages. , 1993, The Journal of biological chemistry.

[21]  T. Tetley.  New perspectives on basic mechanisms in lung disease. 6. Proteinase imbalance: its role in lung disease. , 1993, Thorax.

[22]  S. Shapiro,et al.  Induction of macrophage metalloproteinases by extracellular matrix. Evidence for enzyme- and substrate-specific responses involving prostaglandin-dependent mechanisms. , 1993, The Journal of biological chemistry.

[23]  P. Jorens,et al.  Interleukin-8: an important chemoattractant in sputum of patients with chronic inflammatory airway diseases. , 1993, The American journal of physiology.

[24]  N. Pride,et al.  Failure of inhaled corticosteroids to modify bronchoconstrictor or bronchodilator responsiveness in middle-aged smokers with mild airflow obstruction. , 1992, Chest.

[25]  A B Thompson,et al.  Aerosolized beclomethasone in chronic bronchitis. Improved pulmonary function and diminished airway inflammation. , 1992, The American review of respiratory disease.

[26]  S. Weiss.  Tissue destruction by neutrophils. , 1989, The New England journal of medicine.

[27]  H. Welgus,et al.  Regulation of the expression of tissue inhibitor of metalloproteinases and collagenase by retinoids and glucocorticoids in human fibroblasts. , 1987, The Journal of clinical investigation.

[28]  R. Stockley,et al.  Elastase inhibitors of sputum sol phase: variability, relationship to neutrophil elastase inhibition, and effect of corticosteroid treatment. , 1986, Thorax.

[29]  A. Janoff,et al.  Levels of elastase activity in bronchoalveolar lavage fluids of healthy smokers and nonsmokers. , 2015, The American review of respiratory disease.

[30]  R. Stevenson,et al.  Effect of corticosteroids on sputum sol-phase protease inhibitors in chronic obstructive pulmonary disease. , 1982, Thorax.

[31]  C. Fletcher.  The Natural history of chronic bronchitis and emphysema: An eight-year study of early chronic obstructive lung disease in working men in London , 1976 .

[32]  P. Gross,et al.  EXPERIMENTAL EMPHYSEMA: ITS PRODUCTION WITH PAPAIN IN NORMAL AND SILICOTIC RATS. , 1965, Archives of environmental health.

[33]  C. Laurell,et al.  The Electrophoretic α;1-Globulin Pattern of Serum in α;1-Antitrypsin Deficiency , 1963 .